A break-up of GlaxoSmithKline (GSK.L) is not something that is being considered "at all" at present, the chairman of Britain's biggest drugmaker said on Thursday.
Philip Hampton, who became chairman a year ago, told GSK's annual meeting that the focus was on boosting the performance of the group's consumer division, which sells products ranging from headache pills to toothpaste.
The pharmaceuticals group is in the process of seeking a new chief executive and is under pressure from some shareholders to examine a spin-off of its consumer health business.
Philip Hampton, who became chairman a year ago, told GSK's annual meeting that the focus was on boosting the performance of the group's consumer division, which sells products ranging from headache pills to toothpaste.
The pharmaceuticals group is in the process of seeking a new chief executive and is under pressure from some shareholders to examine a spin-off of its consumer health business.
